 |
Previous Article | Next Article 
The Journal of Neuroscience, July 1, 2002, 22(13):5365-5373
Heparin-Binding Epidermal Growth Factor-Like Growth Factor:
Hypoxia-Inducible Expression In Vitro and Stimulation of
Neurogenesis In Vitro and In Vivo
Kunlin
Jin1,
Xiao Ou
Mao1,
Yunjuan
Sun1,
Lin
Xie1,
Lan
Jin1,
Eiichiro
Nishi2,
Michael
Klagsbrun2, and
David A.
Greenberg1
1 Buck Institute for Age Research, Novato, California
94945, and 2 Departments of Surgical Research and
Pathology, Children's Hospital and Harvard Medical School, Boston,
Massachusetts 02115
 |
ABSTRACT |
Heparin-binding epidermal growth factor (EGF)-like growth factor
(HB-EGF) is found in cerebral neurons, and its expression is
increased after hypoxic or ischemic injury, which also stimulates neurogenesis. To investigate the possible role of HB-EGF in
hypoxic-ischemic induction of neurogenesis, we measured its
expression, effects, and target receptors in embryonic murine cerebral
cortical cultures and in adult rat brain. Hypoxia increased HB-EGF
expression by ~50% in cortical cultures, where expression was
associated with mature and immature neurons. HB-EGF (5-100 ng/ml)
stimulated by ~80% the incorporation of bromodeoxyuridine (BrdU)
into cultured cells that expressed the HB-EGF receptors epidermal
growth factor receptor (EGFR)/avian erythroblastic leukemia viral
oncogene homolog 1 (ErbB1) and N-arginine dibasic
convertase (NRDc). Intracerebroventricular administration of HB-EGF in
adult rats increased BrdU labeling in the subventricular zone and in
the subgranular zone of dentate gyrus, where EGFR/ErbB1 and NRDc were
also expressed and where ischemia-induced neurogenesis is observed. We
conclude that HB-EGF stimulates neurogenesis in proliferative zones of
the adult brain that are also affected in ischemia and that it does so
by interacting with EGFR/ErbB1 and possibly NRDc. Therefore, HB-EGF may
help to trigger proliferation of neuronal precursors in brain after hypoxic or ischemic injury.
Key words:
neurogenesis; hypoxia; ischemia; heparin-binding
epidermal growth factor-like growth factor (HB-EGF); epidermal growth
factor receptor (EGFR/ErbB1); N-arginine dibasic convertase
(NRDc)
 |
INTRODUCTION |
Heparin-binding epidermal growth
factor (EGF)-like growth factor (HB-EGF) is an 87 amino acid mitogenic
and chemotactic glycoprotein containing an EGF-like domain with six
conserved cysteine residues (Higashiyama et al., 1991 ). HB-EGF is
released from cells (Gechtman et al., 1999 ; Dong and Wiley, 2000 ) and
acts through the tyrosine kinase EGF receptor (EGFR)/avian
erythroblastic leukemia viral oncogene homolog 1 (ErbB1) (Raab and
Klagsbrun, 1997 ; Davis-Fleischer and Besner, 1998 ; Jost et al., 2000 ),
but it also acts through EGF-insensitive receptors, including ErbB4,
heparan sulfate proteoglycan (HSPG) (Raab and Klagsbrun, 1997 ), and the
metalloendopeptidase, N-arginine dibasic convertase (NRDc)
(Nishi et al., 2001 ). Downstream signaling by EGF family members
involves the activation of protein kinase cascades (Jost et al., 2000 )
and nuclear translocation of EGF receptors, which may act as
transcription factors (Lin et al., 2001b ). The membrane-bound HB-EGF
precursor, pro-HB-EGF, also binds diphtheria toxin (Naglich et al.,
1992 ) and the anti-apoptotic protein Bag1 (Lin et al., 2001a ).
HB-EGF is widely distributed in neurons and neuroglia throughout the
brain (Mishima et al., 1996 ; Hayase et al., 1998 ), where it is
expressed in both proliferating and post-mitotic cells of prenatal and
postnatal rats (Nakagawa et al., 1998 ). HB-EGF mRNA and protein are
induced in hippocampal CA3 and dentate gyrus (DG) neurons after global
cerebral ischemia (Kawahara et al., 1999 ) and neonatal
hypoxic-ischemic injury (Tanaka et al., 1999 ) in the rat. HB-EGF mRNA
and protein are also induced in rat hippocampus by kainic acid, and
HB-EGF protects cultured hippocampal neurons from kainate toxicity
(Opanashuk et al., 1999 ). These findings are consistent with a
neuroprotective role for HB-EGF in ischemia and related insults.
Ischemia and other cerebral injuries stimulate neurogenesis in
neuroproliferative regions of the adult brain, including the rostral
subventricular zone (SVZ) and the subgranular zone (SGZ) of the
hippocampal DG (Gould and Tanapat, 1997 ; Parent et al., 1997 ; Liu et
al., 1998 ; Takagi et al., 1999 ; Gu et al., 2000 ; Magavi et al., 2000 ;
Jin et al., 2001 ; Yoshimura et al., 2001 ; Zhang et al., 2001 ). Growth
factors such as fibroblast growth factor-2 (FGF-2) seem to be important
mediators of this phenomenon because post-ischemic neurogenesis is
attenuated in FGF-2 knock-out mice and restored when exogenous FGF-2 is
supplied (Yoshimura et al., 2001 ). Some evidence also points to a role
for HB-EGF in neurogenesis, because HB-EGF increases the proliferation
of neuroblasts from the external granular layer of the cerebellum, as
measured by the incorporation of
[3H]thymidine in vitro
(Opanashuk and Hauser, 1998 ).
The observations that (1) HB-EGF is induced by cerebral hypoxia or
ischemia (Kawahara et al., 1999 ; Tanaka et al., 1999 ) and (2) HB-EGF
stimulates neurogenesis in neonatal cerebellar neuroblast cultures
(Opanashuk and Hauser, 1998 ) raise the possibility that HB-EGF might be
involved in hypoxia- and ischemia-induced neurogenesis in the adult
brain. Therefore, we investigated whether HB-EGF protein expression is
induced by neuronal hypoxia in vitro and whether HB-EGF
reproduces the effect of neuronal hypoxia or ischemia on neurogenesis
both in vitro and in vivo.
 |
MATERIALS AND METHODS |
Animal experiments were approved by local committee review and
conducted according to policies on the use of animals of The Society
for Neuroscience.
Cell culture. Cortical neuron cultures were prepared from
16 d Charles River CD1 mouse embryos as described (Sun et al.,
2001 ), except that Neurobasal medium containing 2% B27 supplement, 2 mM glutamate, and 1% penicillin and streptomycin
(Invitrogen, Rockville, MD) was used (Brewer et al., 1993 ). After
4 d, one-half of the medium was replaced with Neurobasal medium
containing 2% B27. Experiments were conducted at 7 d in
vitro.
Hypoxia. To induce hypoxia, cultures were placed in modular
incubator chambers (Billups-Rothenberg, Del Mar, CA) for 0-24 hr at
37°C in humidified 95% air/5% CO2 (control)
or humidified 95% N2/5% CO2
(hypoxia) (Goldberg and Choi, 1993 ; Koretz et al., 1994 ). Cultures were
then returned to normoxic conditions for the remainder, if any, of 24 hr.
Western blotting. Cell lysates were extracted in PBS, pH
7.5, containing 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 µg/ml of aprotinin, and 100 µg/ml of PMSF, and protein
concentration was determined using a Bio-Rad protein assay (Bio-Rad,
Hercules, CA). Protein (100 µg per lane) was boiled at 100°C in SDS
sample buffer for 5 min, electrophoresed by 15% SDS-PAGE, and
transferred to polyvinylidene difluoride membranes. These were
incubated overnight at 4°C with a goat polyclonal anti-HB-EGF
antibody directed against an epitope mapping at the C terminus of mouse
HB-EGF (Santa Cruz Biotechnology, Santa Cruz, CA; 1:250), which does
not cross-react with EGF. Membranes were washed with PBS containing
0.1% Tween-20, incubated at room temperature for 60 min with
horseradish peroxidase-conjugated anti-goat secondary antibody (Santa
Cruz Biotechnology; 1:3000), and washed three times (15 min each) with
PBS/Tween-20. Peroxidase activity was visualized with a
chemoluminescence substrate system (NEN Life Science Products, Boston,
MA). Differences in protein expression on Western blots were quantified
using a GS-710 calibrated imaging densitometer and Quantity One
software (Bio-Rad).
Immunocytochemistry. Cultures were fixed with 4%
paraformaldehyde in PBS for 30 min at room temperature and incubated
with blocking buffer (2% horse serum, 1% BSA, and 0.1% Triton X-100 in PBS, pH 7.5). Primary antibodies were added at 4°C overnight and
included the following: goat polyclonal anti-HB-EGF (Santa Cruz
Biotechnology; 1:100), mouse monoclonal anti-BrdU (Roche, Indianapolis,
IN; 2 µg/ml), sheep polyclonal anti-BrdU (Biodesign, Saco, ME; 25 µg/ml), mouse monoclonal anti-neuronal nuclear antigen (NeuN)
(Chemicon, Temecula, CA; 1:200), mouse monoclonal anti-MAP2 (Sigma, St.
Louis, MO; 1:100), mouse monoclonal anti-rat nestin (BD PharMingen, San
Diego, CA; 1:400), mouse monoclonal anti- III-tubulin (Caltag
Laboratories, Burlingame, CA; 1:400), rabbit polyclonal anti-EGFR/erbB1
(Santa Cruz Biotechnology; 1:100), mouse monoclonal and goat polyclonal
anti-ErbB4 (Santa Cruz Biotechnology; 1:100), and rabbit polyclonal
anti-NRDc raised against a fusion protein of the acidic stretch of rat
NRDc (amino acids 127-214) and glutathione S-transferase
(1:300). The secondary antibodies were fluorescein isothiocyanate
(FITC)-conjugated goat anti-mouse IgG, FITC-conjugated goat anti-rabbit
IgG (Vector, Burlingame, CA; 1:200), and FITC-conjugated pig anti-goat
IgG, rhodamine-conjugated rat-absorbed donkey anti-mouse IgG,
rhodamine-conjugated rat-absorbed donkey anti-rabbit IgG, and
rhodamine-conjugated rat-absorbed donkey anti-sheep IgG (Jackson ImmunoResearch, West Grove, PA; 1:200). DAPI (Vector) was used to
counterstain nuclei, and fluorescence signals were detected with a
Nikon E300 microscope at excitation/emission wavelengths of 535/565 nm
(rhodamine, red), 470/505 (FITC, green), and 360/400 (DAPI, blue).
Results were recorded with a Magnifire digital camera (ChipCoolers,
Warwick, RI). Controls included omitting or preabsorbing the primary
antibody and omitting the secondary antibody.
BrdU labeling in vitro. For immunocytochemical detection,
BrdU (Sigma; 50 µg/ml) was added to cultures for 24 hr. Cultures were
fixed in 4% paraformaldehyde in PBS for 40 min, washed with PBS,
incubated for 2 hr with blocking buffer (2% horse serum, 1% BSA, and
0.1% Triton X-100 in PBS, pH 7.5), incubated overnight at 4°C with
mouse monoclonal anti-BrdU primary antibody (Roche; 2 µg/ml), and
then incubated for 1 hr at room temperature with rhodamine-conjugated
goat anti-mouse IgG secondary antibody (Jackson ImmunoResearch; 1:200).
BrdU-immunoreactive cells were counted in five microscope fields per
well (center and 3, 6, 9, and 12 o'clock). In some experiments, BrdU
incorporation was measured using a commercially available enzyme-linked
immunosorbent assay kit (Roche) (Law et al., 1996 ). In these
experiments, growth factors were added to cultures for 24 hr and then
BrdU was added for 4 hr; in some cases, HB-EGF was added together with
a neutralizing mouse monoclonal antibody against EGFR/ErbB1 (clone 225;
NeoMarkers, Fremont, CA).
Cell viability. Cell viability was assayed by incubating
cells with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, 5 mg/ml; Sigma) at 37°C for 2 hr. Medium was removed, and cells were solubilized with dimethylsulfoxide and transferred to
96-well plates. Absorbance at 570 nm was measured in a Cytofluor 4000 plate-reader (PerSeptive Biosystems, Framingham, MA). Results were
expressed as a percentage of control absorbance, measured in normoxic
cultures, after subtracting background absorbance measured in
freeze-thawed cultures.
Retroviral infection. Humanized Renilla
reniformis green fluorescent protein (hrGFP) was cloned downstream
of the viral promoter of pFB retroviral vector (Stratagene, La Jolla,
CA). The vector was produced by transiently transfecting NIH 3T3 cells
with two additional vectors expressing gag-pol and vesicular stomatitis virus G envelope protein. pFB-hrGFP supernatant containing 4.9 × 10 7 infectious virus particles was
filtered through a 0.45 µm filter and frozen at 80°C. Ten
microliters of retroviral supernatant were added to cultures in
four-well plates containing 500 µl of medium and incubated at 37°C
for 2 d and then for 24 hr in normoxic or hypoxic conditions.
GFP-expressing cells were detected with a Nikon E300 microscope with
excitation at 470 and emission at 505 nm.
HB-EGF and BrdU administration in vivo. Adult (8-10 week)
male Sprague Dawley rats weighing 280-310 gm were anesthetized with 4% isoflurane in 70% N2O/30%
O2 and implanted with an osmotic minipump (Alzet
1003D; Alza Scientific Products, Mountain View, CA). The cannula was
placed in the right lateral ventricle 4.0 mm deep to the pial surface,
+0.8 mm anteroposterior relative to bregma, and 1.3 mm lateral to the
midline. Each rat was infused for 3 d with 1 µl/hr of either
recombinant human HB-EGF (1 µg/ml, R&D Systems, Minneapolis, MN) in
artificial CSF (aCSF) containing (in mM): 128 NaCl, 2.5 KCl, 0.95 CaCl2, 1.99 MgCl2
(n = 4) or aCSF alone (n = 6). BrdU (50 mg/kg, Sigma) was dissolved in saline and given intraperitoneally twice
daily at 8 hr intervals, for the same 3 consecutive days, and rats were
killed 1 week later.
BrdU immunohistochemistry in brain sections. Brains (four
per condition) were removed after perfusion with saline and 4%
paraformaldehyde in PBS. Adjacent 50 µm sections, corresponding to
coronal coordinates interaural 8.7-10.2 mm, bregma 0.30 to bregma
1.2 mm (SVZ), and interaural 4.48-5.86 mm, bregma 4.52 to bregma
3.14 (DG), were cut with a cryostat and stored at 80°C. Sections
were pretreated with 50% formamide, 280 mM NaCl,
and 30 mM sodium citrate at 65°C for 2 hr,
incubated in 2 M HCl at 37°C for 30 min, and
rinsed in 0.1 M boric acid, pH 8.5, at room
temperature for 10 min. Sections were incubated in 1%
H2O2 in PBS for 15 min, in
blocking solution (2% goat serum, 0.3% Triton X-100, and 0.1% bovine
serum albumin in PBS) for 2 hr at room temperature, and with 2 µg/ml
of mouse monoclonal anti-BrdU antibody (Roche) at 4°C overnight.
Sections were washed with PBS, incubated with biotinylated goat
anti-mouse secondary antibody (Vector, 1:200) for 2 hr at 25°C,
washed, and placed in avidin-peroxidase conjugate (Vector) solution
for 1 hr. The horseradish peroxidase reaction was detected with 0.05% diaminobenzidine (DAB) and 0.03%
H2O2. Processing was
stopped with H2O, and sections were dehydrated
through graded alcohols, cleared in xylene, and coverslipped in
permanent mounting medium (Vector). Sections were examined with a Nikon
E300 epifluorescence microscope.
For double immunolabeling studies, sections were fixed with 4%
paraformaldehyde in PBS for 1 hr at room temperature, washed twice with
PBS, and incubated in 2 M HCl at 37°C for 1 hr. After washing again, sections were incubated with blocking solution, then
with primary antibodies at 4°C overnight, and with secondary antibodies in blocking solution at room temperature for 2 hr. The
primary antibodies used were mouse monoclonal anti-BrdU (Roche; 2 µg/ml) and affinity-purified goat polyclonal anti-NeuroD (1:100, Santa Cruz Biotechnology), and the secondary antibodies were
rhodamine-conjugated rat-absorbed donkey anti-mouse IgG (Jackson
ImmunoResearch; 1:200) and FITC-conjugated pig anti-goat IgG (Jackson
ImmunoResearch; 1:200). Sections were mounted with Vectashield
(Vector), and fluorescence signals were detected with a Nikon E800
microscope at excitation/emission wavelengths of 535/565 nm (rhodamine,
red) and 470/505 (FITC, green). Results were recorded with a Magnifire
digital camera (ChipCoolers). For confocal microscopy, a Nikon PCM-2000
laser-scanning confocal microscope and Simple PCI imaging software
(Compix) were used.
BrdU-immunopositive cell counting. BrdU-positive cells in
SGZ and SVZ were counted blindly in five to seven DAB-stained, 50 µm
coronal sections per animal, spaced 200 µm apart. Cells were counted
under high-power (200×) on a Nikon E300 microscope with a Magnifire
digital camera, and the image was displayed on a computer monitor.
Results were expressed as the average number of BrdU-positive cells per section.
Data analysis. Quantitative data were expressed as mean ± SEM from at least three experiments. ANOVA and Student's
t test were used for statistical analysis, with
p < 0.05 considered significant.
 |
RESULTS |
Cellular composition of cultures
At 7 d in vitro, cultures contained primarily
cells of neuronal lineage, as determined by the expression of cell
type-specific markers (Table 1), and the
expression of non-neuronal markers was not altered by hypoxia.
Hypoxia induces HB-EGF expression in cortical cultures
To determine the effect of hypoxia on the expression of HB-EGF
protein, cortical cultures were exposed to hypoxia for 0-24 hr, and
HB-EGF expression was measured by Western blotting. The polyclonal
anti-HB-EGF antibody used does not cross-react with other EGF-family
members, including EGF. Accordingly, as shown in Figure
1, a band was labeled at ~22 kDa, as
predicted for HB-EGF [which shows anomalous, retarded migration on
SDS-PAGE gels caused by heavy glycosylation and positively charged
domains (Raab and Klagsbrun, 1997 )] but not at ~7 kDa, the
anticipated Mr for EGF. HB-EGF expression
increased over basal levels after 4-8 hr of hypoxia and declined with
more prolonged hypoxic exposure. Maximal induction, observed at 4 hr,
reached ~150% of control levels. HB-EGF expression was localized to
the cytoplasmic compartment by immunocytochemistry, consistent with
findings in rat brain (Hayase et al., 1998 ). HB-EGF was present in
mature neurons that expressed NeuN or MAP2, immature neurons expressing
III tubulin, and neuroepithelial precursor cells, which express
nestin (Fig. 2).

View larger version (33K):
[in this window]
[in a new window]
|
Figure 1.
Hypoxia induces the expression of HB-EGF protein
in cerebral cortical cultures. Cultures were exposed to hypoxia for up
to 24 hr, and HB-EGF expression was measured by Western blotting
(A), which showed a hypoxia-induced increase in
the expression of HB-EGF at 4-8 hr. The increase in cellular
expression of HB-EGF was quantified by computer densitometry
(B), which showed that maximal induction,
observed at 4 hr, reached 153 ± 13% of control levels (range,
139-179%; n = 3). HB-EGF expression was localized
to the neuronal cytoplasm by immunocytochemistry (C,
arrowheads; original magnification, 40×). Data are
representative (A, C) or means (B)
of at least three independent experiments.
|
|

View larger version (46K):
[in this window]
[in a new window]
|
Figure 2.
Hypoxia-inducible expression of HB-EGF is
associated with both mature and immature neurons. A,
Cultures were exposed to hypoxia for 8 hr and labeled with an antibody
against a marker of mature neurons (NeuN,
MAP2), immature neurons ( III-tubulin),
or neuroepithelial precursor cells (Nestin)
(a); an antibody against HB-EGF
(b); and the nuclear stain DAPI
(c). Merged images are shown in d.
NeuN-, MAP2-, III-tubulin-, and nestin-immunopositive cells all
coexpressed HB-EGF. B, Cultures were treated with BrdU,
exposed to hypoxia for 8 hr, and labeled with an antibody against BrdU
(a); an antibody against the mature neuronal
marker NeuN, the late immature to mature neuronal marker Hu, the
neuroepithelial precursor cell marker nestin, or the astroglial marker
GFAP (b); and the nuclear stain DAPI
(c). Merged images are shown in d.
Only nestin-immunopositive cells were labeled with BrdU. Data in
A and B are representative fields from at
least three independent experiments per row. Original magnification,
40×.
|
|
HB-EGF stimulates neurogenesis in mouse cerebral
cortical cultures
To determine whether HB-EGF stimulates neurogenesis, BrdU was
added to cortical cultures to label cells undergoing mitosis (S-phase
of the cell cycle), and cultures were maintained for 24 hr under
normoxic conditions in the presence of 0-100 ng/ml of HB-EGF. In these
cultures, BrdU incorporation colocalizes with markers of cell division,
including the proliferating cell nuclear antigen (Ino and Chiba, 2000 ),
the mitotic chromosome condensation marker phospho-histone-H3 (Hendzel
et al., 1997 ), and the replication-licensing protein CDC47 (Fujita et
al., 1996 ), but not with markers of cell injury (Chen et al., 1997 ; Jin
et al., 1999 ), such as labeling with the Klenow fragment of DNA
polymerase I, DNA polymerase I-mediated biotin-dATP nick translation
labeling, or terminal deoxynucleotidyl transferase-mediated
biotinylated UTP nick end labeling (our unpublished data).
Figure 3A shows that HB-EGF
increased BrdU labeling by ~80% over control levels. The effect was
maximal between 5 and 100 ng/ml, which is consistent with the range of
HB-EGF concentrations (10-100 ng/ml) that protect cultured hippocampal
neurons from kainate toxicity (Opanashuk et al., 1999 ). Most cells
labeled by BrdU in the presence of HB-EGF expressed neuronal precursor and immature neuronal markers (Fig. 3C), and the effect of
HB-EGF was associated with increases in the percentage of cells
expressing markers of neuronal lineage (Table 1).

View larger version (21K):
[in this window]
[in a new window]
|
Figure 3.
HB-EGF stimulates BrdU incorporation and increases
the number of viable cells in cerebral cortical cultures. Treatment of
normoxic cultures for 24 hr with HB-EGF increased both BrdU
incorporation measured by ELISA (A) and the
number of viable cells, measured by MTT absorbance
(B). Most cells stimulated to incorporate BrdU in
the presence of HB-EGF expressed markers of immature neurons
(ENCAM) or neuroepithelial precursor cells
(Nestin), whereas few or no BrdU-labeled cells expressed
markers of more mature neurons (Hu,
NeuN), astroglia (GFAP), microglia
(CD11b), or endothelial cells
(CD146). Data are mean ± SEM;
n = 3.
|
|
HB-EGF increases the number of viable cells in
cortical cultures
If HB-EGF stimulates neurogenesis, then it should increase the
number of viable cells in culture. To test this hypothesis, cultures
were maintained for 24 hr in the presence of 0-100 ng/ml of HB-EGF,
and cell viability was measured by MTT absorbance and by cell counting.
At concentrations similar to those associated with increased
incorporation of BrdU, HB-EGF increased MTT absorbance by as much at
40% (Fig. 3B). Because MTT absorbance
measures cell viability as a function of metabolic
activity, and because it is conceivable that an increase in MTT
absorbance could result from an increase in metabolic activity per cell
rather than an increase in cell number, we also counted cells in
control and HB-EGF-treated cultures. Cell counts increased to 125 ± 7% of control values (n = 15) in cultures exposed
for 24 hr to 10 ng/ml of HB-EGF, confirming that HB-EGF stimulates cell proliferation.
Mechanism for stimulation of neurogenesis by HB-EGF
HB-EGF exerts its biological effects by interacting with various
receptors, the best characterized of which are the tyrosine kinase EGF
receptor EGFR/ErbB1 (Raab and Klagsbrun, 1997 ; Davis-Fleischer and
Besner, 1998 ; Jost et al., 2000 ) and the EGF-insensitive tyrosine kinase receptor ErbB4 (Raab and Klagsbrun, 1997 ). To evaluate which of
these receptors might mediate the neuroproliferative effect of HB-EGF,
we first measured BrdU incorporation into cortical neuron cultures
treated for 24 hr with 10 ng/ml of HB-EGF or 10 ng/ml of EGF or both
growth factors in combination. Figure 4
shows that HB-EGF and EGF stimulated BrdU incorporation to similar
extents and that their effects were not additive, which is consistent with a shared mechanism of action.

View larger version (16K):
[in this window]
[in a new window]
|
Figure 4.
Effects of HB-EGF, EGF, and both in combination on
BrdU incorporation in cerebral cortical cultures. Normoxic cultures
were exposed for 24 hr to 10 ng/ml of HB-EGF, 10 ng/ml of EGF, or a
combination of the two. BrdU was added for 4 hr, and BrdU incorporation
was determined by ELISA. Data are mean ± SEM
(n = 3). *p < 0.05 relative to
None (ANOVA and post hoc t
tests).
|
|
To address this issue more directly, HB-EGF- and BrdU-treated
cultures were immunostained for cell proliferation markers (BrdU or
GFP, expressed via a retroviral vector that infects dividing cells) and
for each of three HB-EGF receptors: EGFR/ErbB1, ErbB4, and NRDc. Many
BrdU- and GFP-labeled cells expressed EGFR/ErbB1 and NRDc, but few
expressed ErbB4 (Fig.
5A,B),
suggesting that cells stimulated to proliferate by HB-EGF were
primarily EGFR/ErbB1 and NRDc positive but ErbB4 negative. Expression
of EGFR/ErbB1 and NRDc was associated with nestin-immunopositive
neuronal precursor cells, whereas expression of ErbB4 was associated
with NeuN-immunopositive neurons (Fig. 5C,D).
These findings are consistent with a role for EGFR/ErbB1 or NRDc or
both in HB-EGF-induced neurogenesis. A shared role for these receptors
has been implicated previously in the ability of HB-EGF to induced
migration of HeLa cells and keratinocytes (Nishi et al., 2001 ).

View larger version (62K):
[in this window]
[in a new window]
|
Figure 5.
Expression of HB-EGF receptors and cell
type-specific markers by cells labeled with BrdU in the presence of
HB-EGF. Normoxic cultures were treated with BrdU
(A) or infected with a GFP-expressing retroviral
vector (pFB-hrGFP) (B) and exposed for 24 hr to
10 ng/ml of HB-EGF. Cells were immunostained for BrdU or GFP and for
the HB-EGF receptors EGFR/ErbB1 (EGFR), ErbB4, and NRDc.
Merged images are shown at right. BrdU and GFP
immunoreactivity colocalized with EGFR/ErbB1 and NRDc but not ErbB4.
Some cultures were also stained for the neuroepithelial precursor cell
marker nestin (C) or the mature neuronal marker
NeuN (D) and for the receptors listed above.
EGFR/ErbB1 and NRDc colocalized with nestin, whereas ErbB4 colocalized
with NeuN. Data are representative fields from at least three
independent experiments per row. Original magnification, 40×.
|
|
To test further the hypothesis that EGFR/ErbB1 is required for
HB-EGF-induced neurogenesis, some cultures were treated with HB-EGF and
BrdU in the presence of a neutralizing antibody against EGFR/ErbB1.
Under these conditions, basal incorporation of BrdU was reduced, and
the ability of HB-EGF to stimulate BrdU incorporation was abolished
(Fig. 6). In contrast, stimulation of
BrdU incorporation by FGF-2 was unaffected by the antibody. This
suggests that both a component of basal BrdU incorporation (which may
be stimulated by the release of endogenous EGF or HB-EGF or both) and
incorporation of BrdU induced by exogenous HB-EGF are mediated through
EGFR/ ErbB1. This result is also consistent with the ability of
the same neutralizing antibody against EGFR/ErbB1 to block EGFR/ErbB1- and NRDc-mediated effects of HB-EGF on cell migration (Nishi et al.,
2001 ).

View larger version (28K):
[in this window]
[in a new window]
|
Figure 6.
Effect of a neutralizing antibody against
EGFR/ErbB1 on HB-EGF-stimulated incorporation of BrdU. Normoxic
cultures were treated with HB-EGF or FGF-2 in the presence of
anti-EGFR/ErbB1 for 24 hr and then exposed to BrdU for 4 hr, and BrdU
incorporation was determined by ELISA. Data are mean ± SEM
(n = 3). *p < 0.05 relative to
No antibody (ANOVA and post hoc
t tests).
|
|
HB-EGF stimulates neurogenesis in vivo
The ability of HB-EGF to stimulate neurogenesis in
vitro suggests that a similar effect might occur in
vivo. To test whether HB-EGF can stimulate neurogenesis in
vivo, HB-EGF was infused into the right lateral ventricle and BrdU
was injected intraperitoneally for 3 d in adult rats, and animals
were killed 1 week later. As shown in
Figures 7 and 8A, the
number of BrdU-immunopositive cells in DG and SVZ increased after
HB-EGF administration, most prominently in SVZ, and especially on the
side of the infusion. HB-EGF infusion also increased the number of
cells in DG and SVZ that were colabeled with antibodies against BrdU
and the immature neuronal marker, NeuroD (Lee et al., 2000 ) (Fig.
8B), indicating that HB-EGF affected cells of
neuronal lineage.

View larger version (165K):
[in this window]
[in a new window]
|
Figure 7.
Effect of intracerebroventricular administration
of HB-EGF on BrdU incorporation in DG and SVZ in vivo.
Adult male rats were treated for 3 d with BrdU, given
intraperitoneally, and with HB-EGF, infused into the right lateral
ventricle; BrdU incorporation on the side of HB-EGF infusion (cannula
side) and on the contralateral side was detected by
immunohistochemistry. Sections through the DG show BrdU labeling of a
similar number of cells in the SGZ on both sides, whereas sections
through the SVZ show more prominent labeling on the cannula side
(original magnification, 4×; insets, 40×). Data are
representative fields from at least three independent
experiments.
|
|

View larger version (20K):
[in this window]
[in a new window]
|
Figure 8.
Quantitation of BrdU incorporation in DG and SVZ
after intracerebroventricular administration of HB-EGF in
vivo. A, Adult male rats were treated for 3 d with BrdU, given intraperitoneally, and with either HB-EGF or
vehicle, infused into the right lateral ventricle. BrdU incorporation
was detected by immunohistochemistry and the number of
BrdU-immunopositive cells in vehicle-treated animals
(Sham, white bars) and on the side
contralateral (Contralateral, shaded
bars) and ipsilateral (Cannula, black
bars) to HB-EGF infusion was counted in DG and SVZ and
expressed as mean ± SEM (n = 3).
*p < 0.05 relative to Sham;
**p < 0.02 relative to Sham.
B, In some experiments, cells immunoreactive for
both BrdU and the immature neuronal marker NeuroD were counted
and expressed as a mean percentage ± SEM (n = 3) of BrdU-immunopositive/NeuroD-immunopositive cells in sham-operated
controls. *p < 0.02 relative to
Sham; **p < 0.001 relative to
Sham.
|
|
To identify the cells that proliferate in response to HB-EGF in
vivo, brain sections from SGZ of HB-EGF- and BrdU-treated rats 1 week after treatment were immunostained for BrdU and for markers of
mature and immature neurons. These double-label studies showed that
most BrdU-immunopositive cells coexpressed NeuroD (Fig.
9). Therefore, HB-EGF stimulates the
proliferation of cells of neuronal lineage in vivo, and most
of these exhibit an immature neuronal phenotype at 1 week.

View larger version (80K):
[in this window]
[in a new window]
|
Figure 9.
BrdU labels NeuroD-immunopositive cells after
intracerebroventricular administration of HB-EGF in
vivo. Adult male rats were treated for 3 d with BrdU,
given intraperitoneally, and with HB-EGF, infused into the right
lateral ventricle. A, Sections through SVZ were double
labeled with antibodies against BrdU (red) and against
the immature neuronal marker NeuroD (green),
which colocalized within cell nuclei in this region
(arrows). Data are representative fields from at least
three independent experiments. Original magnification, 40×.
B, Confocal imaging was used to confirm colocalization
of BrdU and NeuroD in the same cells. Scale bar, 20 µm.
|
|
Finally, because our in vitro studies suggested that
the neuroproliferative effect of HB-EGF might be mediated through the EGFR/ErbB1 receptor, we sought to determine whether the distribution of
this receptor in rat brain could account for the distribution of
BrdU labeling induced by HB-EGF in vivo. As shown in
Figure 10, EGFR/ErbB1 and NRDc were
expressed much more abundantly in SVZ than in SGZ, which is consistent
with the more prominent (~5-fold as opposed to ~1.5-fold)
stimulation of BrdU labeling by HB-EGF in SVZ. In contrast, ErbB4 was
barely detectable in SVZ or in SGZ, although it was expressed in nearby
cells, including those of the DG hilus.

View larger version (95K):
[in this window]
[in a new window]
|
Figure 10.
Distribution of HB-EGF receptor expression in
neuroproliferative zones of the adult rat brain. Brain sections from
normal adult male rats were immunostained for each HB-EGF receptor
(EGFR/ErbB1, NRDc, and ErbB4). There was little expression of these
receptors in the SGZ of DG (top panels, dotted
lines), whereas EGFR/ErbB1 and ErbB4 were expressed in cells of
the DG hilus (between dotted lines). EGFR/ErbB1 and NRDc
were expressed prominently, but ErbB4 only weakly, in SVZ (original
magnification, 4×; insets, 40×).
Rectangles in bottom row are 250 × 75 µm.
|
|
 |
DISCUSSION |
Ischemic brain injury triggers molecular and cellular repair
mechanisms that contribute to recovery and may include ischemic activation of neurogenesis in the adult brain (Cramer and Chopp, 2000 ).
Several studies have shown that global or focal cerebral ischemia
stimulates neurogenesis, typically defined by increased incorporation
of BrdU into cells that express neuronal marker proteins, in SGZ, SVZ,
or cerebral cortex (Liu et al., 1998 ; Takagi et al., 1999 ; Gu et al.,
2000 ; Jiang et al., 2001 ; Jin et al., 2001 ; Yoshimura et al.,
2001 ; Zhang et al., 2001 ). Little is known about the mechanisms that
couple cerebral ischemia to neurogenesis, but in one study,
incorporation of BrdU into NeuN-immunopositive hippocampal cells after
ischemia was reduced in FGF-2 knock-out mice and restored by
intracerebroventricular administration of an FGF-2-expressing herpes
simplex virus amplicon vector (Yoshimura et al., 2001 ).
We and others have used an in vitro model of ischemia in
which cerebral cortical cultures are deprived of oxygen or glucose or
both to investigate molecular and cellular mechanisms that may be
involved in cerebral ischemia in vivo (Goldberg and Choi, 1993 ; Koretz et al., 1994 ). Here, we have used this system to identify
factors that are released during hypoxia and can stimulate neurogenesis
in vitro. We report that HB-EGF is one such factor and that
it appears to act through the EGF receptor, ErbB1. Moreover, HB-EGF
stimulates neurogenesis in proliferative zones of the adult brain SVZ
and, to a lesser extent, SGZ when administered into the lateral
ventricle. Thus, the effect of HB-EGF is observed in two distinct
experimental systems: embryonic mouse cortical cultures in
vitro and adult rat brain in vivo.
EGF has been known previously to promote the proliferation of neuronal
precursors (Reynolds et al., 1992 ). Although EGF and HB-EGF are both
members of the EGF family of growth factors, which contain
6-cysteine EGF-like domains with the structure
CX7CX4CX10CXCX8C (Raab and Klagsbrun, 1997 ), their extent of homology is otherwise limited (~20% at the amino acid level) (Higashiyama et al., 1991 ). The EGF-like domain cannot account for the full range of the biological activity of HB-EGF, which depends on binding to ErbB4, HSPG, and NRDc
as well as to the EGF-sensitive receptor, EGFR/ErbB1 (Raab and
Klagsbrun, 1997 ). Nevertheless, the neuroproliferative effect of HB-EGF
in our cell culture system appeared to operate through mechanisms
shared with EGF, because both growth factors increased BrdU
incorporation to a similar extent, their effects were not additive, and
the effect of HB-EGF involved the EGF-sensitive receptor
EGFR/ErbB1.
In a previous study of ischemia-induced neurogenesis in
vivo, we found that focal ischemia produced by middle cerebral
artery occlusion increased BrdU labeling in SVZ and SGZ to a similar extent (Jin et al., 2001 ). In the present study, however, the HB-EGF-induced increase in labeling was greater in SVZ (~400%) than
in SGZ (~65%), which may be related to the more abundant expression
of the HB-EGF receptor, EGFR/ErbB1, on neuronal precursor cells of the
SVZ than those in the SGZ. This result is consistent with the
observation that intracerebroventricular administration of EGF (as well
as of FGF-2) increased the number of progenitor cells in SVZ but not
SGZ (Kuhn et al., 1997 ). However, it is also possible that
differences in local HB-EGF levels after intraventricular infusion
might account in part for the differences in BrdU incorporation observed in SVZ and SGZ.
Both ischemia (Jin et al., 2001 ) and HB-EGF stimulate neurogenesis in
the brain bilaterally, even when ischemia is unilateral. One
explanation for this finding is that the neuroproliferative effect of
ischemia might be mediated through the release of soluble growth
factors that can reach distant brain regions through the cerebrospinal
fluid. In support of this possibility, increased levels of some growth
factors can be found in the cerebrospinal fluid after stroke (Krupinski
et al., 1998 ). In addition, intraventricular administration of several
growth factors, including EGF, FGF-2, and BDNF, can enhance
neurogenesis in neuroproliferative zones of the adult brain in
vivo (Kuhn et al., 1997 ; Zigova et al., 1998 ; Pencea et al.,
2001 ).
The ability of pathological lesions to activate cytoproliferative
processes that contribute to tissue repair, such as angiogenesis, is
well established. Neurogenesis may be another such process, because the
capacity for neurogenesis persists in the adult brain and because
various neuropathological conditions, including ischemia, seizures, and
trauma, trigger increased incorporation of BrdU into what appear to be
proliferating neuronal precursors. Important questions about this
phenomenon remain unresolved, however, including how injured brain
tissue transmits proliferation signals to areas that harbor precursor
cells, whether these cells achieve a fully mature neuronal phenotype,
and the extent to which neurogenesis in the injured adult brain can
restore cerebral function. Our results may help to address the first of
these questions and indicate that the interaction between
hypoxia-inducible HB-EGF and EGFR/ErbB1 may deliver a
neuroproliferative signal to SVZ precursors in the ischemic brain.
 |
FOOTNOTES |
Received Dec. 11, 2001; revised April 1, 2002; accepted April 1, 2002.
This work was supported by United States Public Health Service Grant NS35965.
Correspondence should be addressed to Dr. David A. Greenberg, Buck
Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945. E-mail: dgreenberg{at}buckinstitute.org.
 |
REFERENCES |
-
Brewer GJ,
Torricelli JR,
Evege EK,
Price PJ
(1993)
Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination.
J Neurosci Res
35:567-576[Web of Science][Medline].
-
Chen J,
Jin K,
Chen M,
Pei W,
Kawaguchi K,
Greenberg DA,
Simon RP
(1997)
Early detection of DNA strand breaks in the brain after transient focal ischemia: implications for the role of DNA damage in apoptosis and neuronal cell death.
J Neurochem
69:232-245[Web of Science][Medline].
-
Cramer SC,
Chopp M
(2000)
Recovery recapitulates ontogeny.
Trends Neurosci
23:265-271[Web of Science][Medline].
-
Davis-Fleischer KM,
Besner GE
(1998)
Structure and function of heparin-binding EGF-like growth factor (HB-EGF).
Front Biosci
3:288-299.
-
Dong J,
Wiley HS
(2000)
Trafficking and proteolytic release of epidermal growth factor receptor ligands are modulated by their membrane-anchoring domains.
J Biol Chem
275:557-564[Abstract/Free Full Text].
-
Fujita M,
Kiyono T,
Hayashi Y,
Ishibashi M
(1996)
hCDC47, a human member of the MCM family. Dissociation of the nucleus-bound form during S phase.
J Biol Chem
271:4349-4354[Abstract/Free Full Text].
-
Gechtman Z,
Alonso JL,
Raab G,
Ingber DE,
Klagsbrun M
(1999)
The shedding of membrane-anchored heparin-binding epidermal-like growth factor is regulated by the Raf/mitogen-activated protein kinase cascade and by cell adhesion and spreading.
J Biol Chem
274:28828-28835[Abstract/Free Full Text].
-
Goldberg MP,
Choi DW
(1993)
Combined oxygen and glucose deprivation in cortical cell culture: calcium-dependent and calcium-independent mechanisms of neuronal injury.
J Neurosci
13:3510-3524[Abstract].
-
Gould E,
Tanapat P
(1997)
Lesion-induced proliferation of neuronal progenitors in the dentate gyrus of the adult rat.
Neuroscience
80:427-436[Web of Science][Medline].
-
Gu W,
Brannstrom T,
Wester P
(2000)
Cortical neurogenesis in adult rats after reversible photothrombotic stroke.
J Cereb Blood Flow Metab
20:1166-1173[Web of Science][Medline].
-
Hayase Y,
Higashiyama S,
Sasahara M,
Amano S,
Nakagawa T,
Taniguchi N,
Hazama F
(1998)
Expression of heparin-binding epidermal growth factor-like growth factor in rat brain.
Brain Res
784:163-178[Medline].
-
Hendzel MJ,
Wei Y,
Mancini MA,
Van Hooser A,
Ranalli T,
Brinkley BR,
Bazett-Jones DP,
Allis CD
(1997)
Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation.
Chromosoma
106:348-360[Web of Science][Medline].
-
Higashiyama S,
Abraham JA,
Miller JA,
Fiddes JC,
Klagsbrun M
(1991)
A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF.
Science
251:936-939[Abstract/Free Full Text].
-
Ino H,
Chiba T
(2000)
Expression of proliferating cell nuclear antigen (PCNA) in the adult and developing mouse nervous system.
Brain Res Mol Brain Res
78:163-174[Medline].
-
Jiang W,
Gu W,
Brännström T,
Rosqvist R,
Wester P
(2001)
Cortical neurogenesis in adult rats after transient middle cerebral artery occlusion.
Stroke
32:1201-1207[Abstract/Free Full Text].
-
Jin K,
Chen J,
Nagayama T,
Chen M,
Sinclair J,
Graham SH,
Simon RP
(1999)
In situ detection of neuronal DNA strand breaks using the Klenow fragment of DNA polymerase I reveals different mechanisms of neuron death after global cerebral ischemia.
J Neurochem
72:1204-1214[Web of Science][Medline].
-
Jin K,
Minami M,
Lan JQ,
Mao XO,
Batteur S,
Simon RP,
Greenberg DA
(2001)
Neurogenesis in dentate subgranular zone and rostral subventricular zone after focal cerebral ischemia in the rat.
Proc Natl Acad Sci USA
98:4710-4715[Abstract/Free Full Text].
-
Jost M,
Kari C,
Rodeck U
(2000)
The EGF receptor
an essential regulator of multiple epidermal functions.
Eur J Dermatol
10:505-510[Web of Science][Medline]. -
Kawahara N,
Mishima K,
Higashiyama S,
Taniguchi N,
Tamura A,
Kirino T
(1999)
The gene for heparin-binding epidermal growth factor-like growth factor is stress-inducible: its role in cerebral ischemia.
J Cereb Blood Flow Metab
19:307-320[Web of Science][Medline].
-
Koretz B,
Ahern KB,
Lustig HS,
Greenberg DA
(1994)
Pre- and postsynaptic modulators of excitatory neurotransmission: comparative effects on hypoxia/hypoglycemia in cortical cultures.
Brain Res
643:334-337[Medline].
-
Krupinski J,
Vodovotz Y LiC,
Slowik A,
Beevers D,
Flanders KC,
Lip G,
Kumar P,
Szczudlik A
(1998)
Inducible nitric oxide production and expression of transforming growth factor-beta1 in serum and CSF after cerebral ischaemic stroke in man.
Nitric Oxide
2:442-453[Web of Science][Medline].
-
Kuhn HG,
Winkler J,
Kempermann G,
Thal LJ,
Gage FH
(1997)
Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain.
J Neurosci
17:5820-5829[Abstract/Free Full Text].
-
Law RE,
Meehan WP,
Xi XP,
Graf K,
Wuthrich DA,
Coats W,
Faxon D,
Hsueh WA
(1996)
Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.
J Clin Invest
98:1897-1905[Web of Science][Medline].
-
Lee JK,
Cho JH,
Hwang WS,
Lee YD,
Reu DS,
Suh-Kim H
(2000)
Expression of neuroD/BETA2 in mitotic and postmitotic neuronal cells during the development of nervous system.
Dev Dyn
217:361-367[Web of Science][Medline].
-
Lin J,
Hutchinson L,
Gaston SM,
Raab G,
Freeman MR
(2001a)
BAG-1 is a novel cytoplasmic binding partner of the membrane form of heparin-binding EGF-like growth factor: a unique role for proHB-EGF in cell survival regulation.
J Biol Chem
276:30127-30132[Abstract/Free Full Text].
-
Lin SY,
Makino K,
Xia W,
Matin A,
Wen Y,
Kwong KY,
Bourguignon L,
Hung MC
(2001b)
Nuclear localization of EGF receptor and its potential new role as a transcription factor.
Nat Cell Biol
3:802-808[Web of Science][Medline].
-
Liu J,
Solway K,
Messing RO,
Sharp FR
(1998)
Increased neurogenesis in the dentate gyrus after transient global ischemia in gerbils.
J Neurosci
18:7768-7778[Abstract/Free Full Text].
-
Magavi SS,
Leavitt BR,
Macklis JD
(2000)
Induction of neurogenesis in the neocortex of adult mice.
Nature
405:951-955[Medline].
-
Mishima K,
Higashiyama S,
Nagashima Y,
Miyagi Y,
Tamura A,
Kawahara N,
Taniguchi N,
Asai A,
Kuchino Y,
Kirino T
(1996)
Regional distribution of heparin-binding epidermal growth factor-like growth factor mRNA and protein in adult rat forebrain.
Neurosci Lett
213:153-156[Web of Science][Medline].
-
Naglich JG,
Metherall JE,
Russell DW,
Eidels L
(1992)
Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor.
Cell
69:1051-1061[Web of Science][Medline].
-
Nakagawa T,
Sasahara M,
Hayase Y,
Haneda M,
Yasuda H,
Kikkawa R,
Higashiyama S,
Hazama F
(1998)
Neuronal and glial expression of heparin-binding EGF-like growth factor in central nervous system of prenatal and early-postnatal rat.
Brain Res Dev Brain Res
108:263-272[Medline].
-
Nishi E,
Prat A,
Hospital V,
Elenius K,
Klagsbrun M
(2001)
N-arginine dibasic convertase is a specific receptor for heparin-binding EGF-like growth factor that mediates cell migration.
EMBO J
20:3342-3350[Web of Science][Medline].
-
Opanashuk LA,
Hauser KF
(1998)
Opposing actions of the EGF family and opioids: heparin binding-epidermal growth factor (HB-EGF) protects mouse cerebellar neuroblasts against the antiproliferative effect of morphine.
Brain Res
804:87-94[Web of Science][Medline].
-
Opanashuk LA,
Mark RJ,
Porter J,
Damm D,
Mattson MP,
Seroogy KB
(1999)
Heparin-binding epidermal growth factor-like growth factor in hippocampus: modulation of expression by seizures and anti-excitotoxic action.
J Neurosci
19:133-146[Abstract/Free Full Text].
-
Parent JM,
Yu TW,
Leibowitz RT,
Geschwind DH,
Sloviter RS,
Lowenstein DH
(1997)
Dentate granule cell neurogenesis is increased by seizures and contributes to aberrant network reorganization in the adult rat hippocampus.
J Neurosci
17:3727-3738[Abstract/Free Full Text].
-
Pencea V,
Bingaman KD,
Wiegand SJ,
Luskin MB
(2001)
Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus.
J Neurosci
21:6706-6717[Abstract/Free Full Text].
-
Raab G,
Klagsbrun M
(1997)
Heparin-binding EGF-like growth factor.
Biochim Biophys Acta
1333:F179-199[Medline].
-
Reynolds BA,
Tetzlaff W,
Weiss S
(1992)
A multipotent EGF-responsive striatal embyronic progenitor cell produces neurons and astrocytes.
J Neurosci
12:4565-4574[Abstract].
-
Sun Y,
Jin K,
Mao XO,
Zhu Y,
Greenberg DA
(2001)
Neuroglobin is upregulated by and protects neurons from hypoxic-ischemic injury.
Proc Natl Acad Sci USA
98:15306-15311[Abstract/Free Full Text].
-
Takagi Y,
Nozaki K,
Takahashi J,
Yodoi J,
Ishikawa M,
Hashimoto N
(1999)
Proliferation of neuronal precursor cells in the dentate gyrus is accelerated after transient forebrain ischemia in mice.
Brain Res
831:283-287[Web of Science][Medline].
-
Tanaka N,
Sasahara M,
Ohno M,
Higashiyama S,
Hayase Y,
Shimada M
(1999)
Heparin-binding epidermal growth factor-like growth factor mRNA expression in neonatal rat brain with hypoxic/ischemic injury.
Brain Res
827:130-138[Web of Science][Medline].
-
Yoshimura S,
Takagi Y,
Harada J,
Teramoto T,
Thomas SS,
Waeber C,
Bakowska JC,
Breakefield XO,
Moskowitz MA
(2001)
FGF-2 regulation of neurogenesis in adult hippocampus after brain injury.
Proc Natl Acad Sci USA
98:5874-5879[Abstract/Free Full Text].
-
Zhang RL,
Zhang ZG,
Zhang L,
Chopp M
(2001)
Proliferation and differentiation of progenitor cells in the cortex and the subventricular zone in the adult rat after focal cerebral ischemia.
Neuroscience
105:33-41[Web of Science][Medline].
-
Zigova T,
Pencea V,
Wiegand SJ,
Luskin MB
(1998)
Intraventricular administration of BDNF increases the number of newly generated neurons in the adult olfactory bulb.
Mol Cell Neurosci
11:234-245[Web of Science][Medline].
Copyright © 2002 Society for Neuroscience 0270-6474/02/22135365-09$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
M. R. Douglas, K. C. Morrison, S. J. Jacques, W. E. Leadbeater, A. M. Gonzalez, M. Berry, A. Logan, and Z. Ahmed
Off-target effects of epidermal growth factor receptor antagonists mediate retinal ganglion cell disinhibited axon growth
Brain,
November 1, 2009;
132(11):
3102 - 3121.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Uetani, H. Nakayama, H. Okayama, T. Okura, J. Higaki, H. Inoue, and S. Higashiyama
Insufficiency of Pro-heparin-binding Epidermal Growth Factor-like Growth Factor Shedding Enhances Hypoxic Cell Death in H9c2 Cardiomyoblasts via the Activation of Caspase-3 and c-Jun N-terminal Kinase
J. Biol. Chem.,
May 1, 2009;
284(18):
12399 - 12409.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T.-Y. Eom, K. A. Roth, and R. S. Jope
Neural Precursor Cells Are Protected from Apoptosis Induced by Trophic Factor Withdrawal or Genotoxic Stress by Inhibitors of Glycogen Synthase Kinase 3
J. Biol. Chem.,
August 3, 2007;
282(31):
22856 - 22864.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. H. Kim, S. J. Won, X. O. Mao, C. Ledent, K. Jin, and D. A. Greenberg
Role for Neuronal Nitric-Oxide Synthase in Cannabinoid-Induced Neurogenesis
J. Pharmacol. Exp. Ther.,
October 1, 2006;
319(1):
150 - 154.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Liu, H. Chen, T. G. Johns, and A. H. Neufeld
Epidermal growth factor receptor activation: an upstream signal for transition of quiescent astrocytes into reactive astrocytes after neural injury.
J. Neurosci.,
July 12, 2006;
26(28):
7532 - 7540.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. R. Armant, B. A. Kilburn, A. Petkova, S. S. Edwin, Z. M. Duniec-Dmuchowski, H. J. Edwards, R. Romero, and R. E. Leach
Human trophoblast survival at low oxygen concentrations requires metalloproteinase-mediated shedding of heparin-binding EGF-like growth factor
Development,
February 15, 2006;
133(4):
751 - 759.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Estrada and M. Murillo-Carretero
Nitric Oxide and Adult Neurogenesis in Health and Disease
Neuroscientist,
August 1, 2005;
11(4):
294 - 307.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D. N. Abrous, M. Koehl, and M. Le Moal
Adult Neurogenesis: From Precursors to Network and Physiology
Physiol Rev,
April 1, 2005;
85(2):
523 - 569.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Sugiura, K. Kitagawa, S. Tanaka, K. Todo, E. Omura-Matsuoka, T. Sasaki, T. Mabuchi, K. Matsushita, Y. Yagita, and M. Hori
Adenovirus-Mediated Gene Transfer of Heparin-Binding Epidermal Growth Factor-Like Growth Factor Enhances Neurogenesis and Angiogenesis After Focal Cerebral Ischemia in Rats
Stroke,
April 1, 2005;
36(4):
859 - 864.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Jin, L. Xie, S. H. Kim, S. Parmentier-Batteur, Y. Sun, X. O. Mao, J. Childs, and D. A. Greenberg
Defective Adult Neurogenesis in CB1 Cannabinoid Receptor Knockout Mice
Mol. Pharmacol.,
August 1, 2004;
66(2):
204 - 208.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Gurok, C. Steinhoff, B. Lipkowitz, H.-H. Ropers, C. Scharff, and U. A. Nuber
Gene Expression Changes in the Course of Neural Progenitor Cell Differentiation
J. Neurosci.,
June 30, 2004;
24(26):
5982 - 6002.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. JIN, X. O. MAO, B. COTTRELL, B. SCHILLING, L. XIE, R. H. ROW, Y. SUN, A. PEEL, J. CHILDS, G. GENDEH, et al.
Proteomic and immunochemical characterization of a role for stathmin in adult neurogenesis
FASEB J,
February 1, 2004;
18(2):
287 - 299.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Jin, A. L. Peel, X. O. Mao, L. Xie, B. A. Cottrell, D. C. Henshall, and D. A. Greenberg
Increased hippocampal neurogenesis in Alzheimer's disease
PNAS,
January 6, 2004;
101(1):
343 - 347.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. H. Shah, M. P. Farshori, and K. J. Catt
Neuropeptide-induced Transactivation of a Neuronal Epidermal Growth Factor Receptor Is Mediated by Metalloprotease-dependent Formation of Heparin-binding Epidermal Growth Factor
J. Biol. Chem.,
January 2, 2004;
279(1):
414 - 420.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. ZHU, K. JIN, X. O. MAO, and D. A. GREENBERG
Vascular endothelial growth factor promotes proliferation of cortical neuron precursors by regulating E2F expression
FASEB J,
February 1, 2003;
17(2):
186 - 193.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Jin, Y. Zhu, Y. Sun, X. O. Mao, L. Xie, and D. A. Greenberg
Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo
PNAS,
September 3, 2002;
99(18):
11946 - 11950.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|